Table 3 Length of follow-up among IPF patients
Cohorts | Length of Follow-Up (in Years) | ||||
|---|---|---|---|---|---|
N | % | Mean (SD) | Median | Interquartile Range | |
IPF Cohort | 4,716 | 100.0 | 1.3 (1.4) | 0.8 | 0.2 - 1.8 |
Reason for Censoring: | |||||
End of Study Period | 1,537 | 32.6 | 1.8 (1.7) | 1.3 | 0.5 - 2.7 |
Death | 1,082 | 22.9 | 0.9 (1.1) | 0.5 | 0.1 - 1.4 |
End of Health Plan Enrollment | 1,289 | 27.3 | 1.2 (1.2) | 0.9 | 0.3 - 1.8 |
Exclusion Criteria Observed | 808 | 17.1 | 0.8 (1.0) | 0.4 | 0.1 - 1.1 |
IPF Diagnostic Testing Subgroup | 2,518 | 100.0 | 1.2 (1.4) | 0.7 | 0.2 - 1.7 |
Reason for Censoring: | |||||
End of Study Period | 793 | 31.5 | 1.8 (1.7) | 1.2 | 0.5 - 2.7 |
Death | 584 | 23.2 | 0.9 (1.1) | 0.4 | 0.1 - 1.2 |
End of Health Plan Enrollment | 661 | 26.3 | 1.2 (1.2) | 0.8 | 0.3 - 1.8 |
Exclusion Criteria Observed | 480 | 19.1 | 0.7 (0.9) | 0.3 | 0.1 - 1.0 |